Morgan Stanley upgraded Gilead Sciences, Inc. GILD from Equal-weight to Overweight Monday and raised its price target from $100 to $104.
Analyst Matthew Harrison felt that price fears were exaggerated. Analysts at Bank of America and Deutsche Bank predicted a possible price war following the decision of Express Scripts to chose AbbVie Inc ABBV as its exclusive supplier of hepatitis C treatments.
Harrison saw an improved risk-to-reward ratio now that shares have declined and felt the company can maintain a 75 percent market share even with the AbbVie price discounts.
Gilead Sciences, Inc. recently traded at $96.86, up 3.27 percent.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.